Phase 1, Open-Label, Single Arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants From 2 to Less Than 12 Years of Age With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis With Antibiotics
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Gepotidacin (Primary)
- Indications Gonorrhoea
- Focus Pharmacokinetics
- Sponsors GSK
Most Recent Events
- 16 Feb 2026 New trial record